Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Down 75.4% in May

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 157,814 shares, a decline of 75.4% from the April 30th total of 642,343 shares. Currently, 11.4% of the shares of the stock are sold short. Based on an average trading volume of 156,698 shares, the short-interest ratio is currently 1.0 days.

Scinai Immunotherapeutics Stock Performance

Shares of Scinai Immunotherapeutics stock traded up $0.00 on Friday, hitting $0.45. The stock had a trading volume of 472,796 shares, compared to its average volume of 2,087,571. Scinai Immunotherapeutics has a 52-week low of $0.41 and a 52-week high of $6.18. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.12. The stock has a market cap of $1.78 million, a price-to-earnings ratio of -0.05 and a beta of 2.19. The company’s 50 day moving average price is $0.58 and its 200 day moving average price is $0.78.

Scinai Immunotherapeutics (NASDAQ:SCNI) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $3.80 EPS for the quarter. The company had revenue of $0.27 million for the quarter.

Institutional Trading of Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC raised its stake in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. Institutional investors own 58.41% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.